Spectrum Pharmaceuticals Inc., of Henderson, Nev., said data published in Blood showed that the addition of Zevalin (ibritumomab tiuxetan) following fludarabine, cyclophosphamide and Rituxan (rituximab, Roche AG and Biogen Idec Inc.) conditioning and nonmyeloablative allogeneic stem cell transplantation resulted in a significantly improved six-year overall survival estimate of 80 percent in chemotherapy-refractory patients with advanced, relapsed non-Hodgkin's lymphoma

placebo in the prevention of cytomegalovirus in 230 hematopoietic stem cell transplant patients showed that those receiving CMX001 had reduced incidences of hematuria and serum creatinine elevations, compared to placebo

Advanced Cell Technology Inc., of Marlborough, Mass., treated the fourth patient – the first of the second patient cohort – in its trial of human embryonic stem cell-derived (hESC) retinal pigment epithelial (RPE) cells in Stargardt's macular dystrophy (SMD

The therapy is designed to work by activating cancer stem cells that hibernate during chemotherapy so they can be destroyed

Neuralstem, Inc., of Rockville, Md., reported that the 16th patient in an ongoing Phase I trial of its spinal cord neural stem cells in amyotrophic lateral sclerosis (ALS) has been treated...That is also the first patient in the trial to receive stem cell transplantation in both regions of the spinal cord and the first patient returning to the trial for a second treatment

Based on the findings, updated from results published in January in Cancer, Spectrum expanded the development program for Zevalin to include support for a larger, randomized international study using the Z-BEAM regimen as a preparative regimen for patients with lymphoma who receive autologous stem cell transplantation

At the 17th Congress of the European Hematology Association in Amsterdam, Max Topp, of the University of Wuerzberg, Germany presented the results of a Phase II study evaluating the efficacy, safety and tolerability of bispecific antibody blinatumomab (Micromet Inc.) in adult patients with B-precursor acute lymphoblastic leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant

Seattle Genetics Inc., of Bothell, Wash., reported updated survival data from a pivotal trial of single-agent Adcetris (brentuximab vedotin) in patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplant, showing that the median overall survival has not been reached after a 26.5-month median follow-up

Those data showed that ICT down-regulates tumor-associated antigens as well as cancer stem cell marker CD-133, in some patients...The results supported the strategy of targeting antigens that are highly expressed by cancer stem cells

The trial, which is evaluating the safety and preliminary efficacy of the company's HuCNS-SC cells (purified human neural stem cells), represents the first time neural stem cells have been transplanted as a potential therapeutic agent for spinal cord injury

Cytomedix Inc., of Gaithersburg, Md., said the independent data safety monitoring board recommended that the Phase II trial of ALD-401, a differentiated stem cell population derived from patients' own bone marrow, can continue as designed, following a review of the safety data on the first 10 patients treated post-acutely for ischemic stroke

JVS-100 is designed to encode stromal cell-derived factor 1, which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow

The HepaStem technology involves the use of allogeneic adult liver stem cells

Celgene International Sarl, a subsidiary of Celgene Corp., of Summit, N.J., said three Phase III trials of Revlimid (lenalidomide) in multiple myeloma supported the growing body of evidence for use of the drug in newly diagnosed patients and in maintenance treatment following autologous stem cell transplant

Neuralstem Inc., of Rockville, Md., said the FDA approved the return of three patients from earlier cohorts in its ongoing Phase I trial testing its spinal cord stem cells (HSSCs) in amyotrophic lateral sclerosis...They will be the first to receive stem cell transplantation along the length of the spinal cord

The cells are derived from human embryonic stem cells (hESCs

Magellan MAR01 is designed to enable the rapid operating room-based "closed system" concentration of aspirated bone marrow, yielding an injectable tissue rich in platelets, hematopoietic stem cells and mesenchymal stem cells in as little as 15 minutes

said final results from a Phase IIb (RESTORE-CLI) trial of ixmyelocel-T, a stem cell therapy for critical limb ischemia, showed improved time to treatment failure (62 percent risk reduction) compared to the control group

StemCells Inc., of Newark, Calif., reported preliminary evidence of progressive and durable donor cell-derived myelination in all four patients who underwent transplantation with the company's HuCNS-SC cells (purified human neural stem cells) in its Phase I trial in Pelizaeus-Merzbacher disease, a rare hypo-myelination disorder in children